240 related articles for article (PubMed ID: 16299296)
1. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
[TBL] [Abstract][Full Text] [Related]
2. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of WRSS1, a
Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
[No Abstract] [Full Text] [Related]
5. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.
Pitisuttithum P; Islam D; Chamnanchanunt S; Ruamsap N; Khantapura P; Kaewkungwal J; Kittitrakul C; Luvira V; Dhitavat J; Venkatesan MM; Mason CJ; Bodhidatta L
Clin Vaccine Immunol; 2016 Jul; 23(7):564-75. PubMed ID: 27146000
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.
Kotloff KL; Taylor DN; Sztein MB; Wasserman SS; Losonsky GA; Nataro JP; Venkatesan M; Hartman A; Picking WD; Katz DE; Campbell JD; Levine MM; Hale TL
Infect Immun; 2002 Apr; 70(4):2016-21. PubMed ID: 11895966
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers.
Sadorge C; Ndiaye A; Beveridge N; Frazer S; Giemza R; Jolly N; Johnson J; Liddy H; Cosgrove CA; Allavena P; Mantovani A; Béchet S; Fontaine-Thompson A; Griffin GE; Dupont F; Sansonetti PJ; Lewis DJ
Vaccine; 2008 Feb; 26(7):978-87. PubMed ID: 18207287
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.
McKenzie R; Venkatesan MM; Wolf MK; Islam D; Grahek S; Jones AM; Bloom A; Taylor DN; Hale TL; Bourgeois AL
Vaccine; 2008 Jun; 26(26):3291-6. PubMed ID: 18468742
[TBL] [Abstract][Full Text] [Related]
10. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH
Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
[TBL] [Abstract][Full Text] [Related]
12. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.
Kotloff KL; Pasetti MF; Barry EM; Nataro JP; Wasserman SS; Sztein MB; Picking WD; Levine MM
J Infect Dis; 2004 Nov; 190(10):1745-54. PubMed ID: 15499528
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
[TBL] [Abstract][Full Text] [Related]
15. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.
Barnoy S; Jeong KI; Helm RF; Suvarnapunya AE; Ranallo RT; Tzipori S; Venkatesan MM
Vaccine; 2010 Feb; 28(6):1642-54. PubMed ID: 19932216
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
Riddle MS; Kaminski RW; Williams C; Porter C; Baqar S; Kordis A; Gilliland T; Lapa J; Coughlin M; Soltis C; Jones E; Saunders J; Keiser PB; Ranallo RT; Gormley R; Nelson M; Turbyfill KR; Tribble D; Oaks EV
Vaccine; 2011 Sep; 29(40):7009-19. PubMed ID: 21787825
[TBL] [Abstract][Full Text] [Related]
17. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.
Katz DE; Coster TS; Wolf MK; Trespalacios FC; Cohen D; Robins G; Hartman AB; Venkatesan MM; Taylor DN; Hale TL
Infect Immun; 2004 Feb; 72(2):923-30. PubMed ID: 14742537
[TBL] [Abstract][Full Text] [Related]
18. Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children.
Sarker P; Mily A; Ara A; Haque F; Maier N; Wierzba TF; Walker RI; Venkatesan MM; Raqib R
J Infect Dis; 2021 Dec; 224(12 Suppl 2):S829-S839. PubMed ID: 34374425
[TBL] [Abstract][Full Text] [Related]
19. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.
Frenck RW; Baqar S; Alexander W; Dickey M; McNeal M; El-Khorazaty J; Baughman H; Hoeper A; Barnoy S; Suvarnapunya AE; Kaminski RW; Venkatesan MM
Vaccine; 2018 Aug; 36(32 Pt B):4880-4889. PubMed ID: 30037478
[TBL] [Abstract][Full Text] [Related]
20. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ
Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
